GENE Solutions Phils.

03/08/2026

From Asia-led evidence to global recognition.
2026 has been a landmark year for SPOT-MAS, with real-world data from six Asian countries highlighted at ASCO and the test receiving U.S. FDA Breakthrough Device Designation*.

31/07/2026

Advancing the future of prenatal screening with real-world evidence and AI-powered analysis.

Advancing the future of prenatal screening with real-world evidence and AI-powered analysis

At ISPD 2026, Gene Solutions presented new evidence demonstrating how routine NIPT can evolve into a more comprehensive tool for maternal and fetal health.
Read the full announcement: https://genesolutions.com/news/gene-solutions-showcases-global-evidence-and-responsible-innovation-in-prenatal-and-womens-genomic-health-at-ispd-2026

Our industry symposium featured presentations by:
▶️Dr. Natalie Chandler, NHS North Thames Genomic Laboratory Hub and NHS Great Ormond Street Hospital for Children, UK
▶️Dr. Sang Hung Tang, Medical Director, Medical Genetics Institute of Ho Chi Minh City, Vietnam
▶️Dr. Hoa Giang, Co-founder and Chief Data Science Officer, Gene Solutions, US
▶️Dr. Minh-Duy Phan, Head of Data Science, Gene Solutions, Australia
▶️Ida Deleskog Lindstroem, Global Medical Affairs Director, Gene Solutions, Singapore

The symposium highlighted:
🔹 Real-world evidence from 225,092 pregnant women across six Asian countries who were screened for 18 common recessive conditions through routine NIPT infrastructure, providing one of the largest real-world datasets on NIPT-integrated carrier screening.
🔹 More than 1 in 4 women were identified as carriers of at least one screened condition, reinforcing the value of integrating carrier screening into routine prenatal care through a single maternal blood draw.
🔹 Emerging research on AI-powered multi-omic analysis showed how molecular signals within existing cfDNA data could help predict pregnancy complications such as gestational diabetes mellitus and preterm birth, without additional blood collection or sequencing.
🔹 From Asia to the world: Since 2018, Gene Solutions’ triSure NIPT has supported prenatal care for millions of pregnant women through thousands of hospitals and clinics across Asia. Backed by a global network of next-generation sequencing laboratories and more than 20 publications on NIPT and genetic landscapes, triSure Procare was presented to a global scientific audience for the first time at ISPD 2026, marking another milestone in Gene Solutions’ expansion across Europe, the Middle East, Africa, and Latin America.

Collectively, the global experts emphasized that the future of prenatal care is not only about generating broader genomic insights, but also about ensuring responsible implementation through robust validation, genetic counselling, and equitable access.

Thank you to everyone who joined us at ISPD 2026 to explore the next chapter of precision prenatal medicine.
Learn more about the technology trusted by millions of pregnant women: https://genesolutions.com/our-test/trisure-procare

24/07/2026

The story of triSure - Gene Solutions' comprehensive NIPT (Non-invasive Prenatal Testing) solutions for all OBGYNs and pregnant women. triSure NGS-based screening products line covers from fetus basic trisomy, mother's carrier integration to single-gene disorders, with validated notable accuracy and unique post-test support.

22/07/2026

Cancer is often silent in its early stages. Detection shouldn't be. Discover SPOT-MAS 10, Multi-Cancer Early Detection!

21/07/2026

Two studies, one shared commitment: engineering ctDNA around real-world constraints to better support clinical decision-making in everyday practice.

🔗 Read the full recap article to explore the data in detail: https://genesolutions.com/.../k-track-at-asco.../
🧬 Explore the K-TRACK portfolio: https://genesolutions.com/our-test/k-track

15/07/2026

What if a single cervical swab could offer deeper insights into cervical cancer and endometrial cancer?
SPOT‑MAS Eva — a methylation-based test for broader gynecologic cancer insight.

Ask your OB-Gynecologist About Spot-Mas EVA!

10/07/2026

Gene Solutions' SPOT-MAS 10 is gaining massive international attention after real-world data from over 84,145 individuals was highlighted by the American Society of Clinical Oncology at ASCO Breakthrough 2026.
🔗 Read the full announcement: https://genesolutions.com/news/gene-solutions-spot-mas-10-places-asia-led-cancer-screening-innovation-in-the-global-spotlight

From blood-based AI innovation to receiving U.S. FDA Breakthrough Device Designation, this Asia-led technology is stepping into the global spotlight to address unmet needs in cancer screening.

08/07/2026

Happening today!

22/06/2026

09/06/2026

We tie the knot of connection to untie the knot of fear. ️
Every cancer survivorship journey deserves to be seen, heard, and supported.

: We tie the knot of connection to untie the knot of fear. ️
Every cancer survivorship journey deserves to be seen, heard, and supported.

This Cancer Survivors Day, inspired by the intertwined threads of the , we aim to foster meaningful conversations around survivorship, advancing early cancer detection, and proactive health.

✨ Join our initiative: Threads of Hope
A knot is always stronger than a single thread. By sharing our stories and sending heartfelt messages, we transform fear into connection—reminding survivors they are never alone.

👉 Share your message of hope here: https://genesolutions.com/cancer-survivors-day/
Beyond community support, we hope these conversations inspire a proactive approach to regular screening. Early detection saves lives.
365 Cancer Prevention Society